Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.

What Was Tested

Researchers studied Amlodipine in this randomized controlled trial publication.

Recently, a novel device for measuring the cardio-ankle vascular index (CAVI) as an arterial stiffness parameter has been developed.

In this study, the researchers evaluated the effect of angiotensin II receptor blocker (ARB) and calcium channel (Ca) blocker on CAVI in type 2 diabetic patients with hypertension.

Who Took Part

According to the abstract, 2 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Seventy type 2 diabetes mellitus patients with hypertension were enrolled and randomly divided into two groups.

How the Study Was Run

The design is described as randomized.

Because people in this Amlodipine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

PubMed files the paper under topics including 8-Hydroxy-2'-Deoxyguanosine, Amlodipine, Angiotensin II Type 1 Receptor Blockers, Ankle, Antihypertensive Agents, Calcium Channel Blockers and Deoxyguanosine.

What This Means in Plain Language

The paper is a randomized study of Amlodipine in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (Journal of atherosclerosis and thrombosis), a journal based in Japan.

More context: all human trials.